Cloud Deployment, quality, and scalability

We know that achieving our goal of becoming a leading global digital Pathology and AI company starts with ensuring the quality of our services and solutions

PharmaNest recognizes that our clients rely on our services and solutions to improve the development of therapeutic compounds and the management of patients affected by fibrotic conditions. We must maintain this trust by adhering to strict quality control standards in the development, validation, deployment, and scalability of our cloud based operations

We are committed to maintaining a comprehensive quality assurance and control program to support our compliance with internationally recognized Good Practice quality guidelines (GxP), especially Software Development, Validation Lifecycle , Good Laboratory Practice (GLP) and Good Clinical Practice (GCP). Furthermore, we require the same level of quality commitment from our suppliers and business partners who provide services for the Company.

Timely reporting of any potential quality concerns is critical to ensuring the integrity of our products. Any potential quality issues or concerns must be reported to the Quality Assurance, Legal or Compliance Departments.

Ethical research

We strive to meet ethical and scientific standards in all of our research activities.

PharmaNest develops novel, innovative digital Pathology image analysis methods to improve the quantification of Fibrosis and its associated histological features. The use of these methods helps our clients and collaborators to improve and accelerate the discovery and development of novel compounds available to patients affected by Fibrotic conditions

Ethical research is fundamental to creating safe, effective medicines and maintaining our credibility with customers At Pharmanest, or in partnership with our clients and collaborators, we expect our employees to conduct all research activities in accordance with the Code, the Company’s policies and applicable procedures and recognized international standards for Good Clinical Practices (GCP) and Good Laboratory Practice (GLP). Attempting to unduly influence research results or falsification of research data is strictly prohibited. We believe in transparency in our research by reporting all results, whether positive or negative.

We respect the rights of individuals involved in our research activities and fully and completely disclose the purpose and nature of the clinical studies in which they participate. While we strive to limit our inbound data to pseudonymized data, we are committed to protect patient privacy and support our clients and partners to establish standards and protocols for the use and storage of patient personal information.

Indirectly, we are committed to support our clients and collaborators to strictly adhere to applicable animal welfare laws, industry codes and standards relating to the responsible treatment of animals in research. In situations that require the use of animals to conduct research, it is our responsibility to ensure that our clients and collaborators treat animals respectfully and with a high level of ethical concern.